N-苯基-N-(4-哌啶)丙胺 混合盐酸 | 1609-66-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-苯基-N-(4-哌啶)丙胺 混合盐酸
• 中文别名: N-苯基-N-(4-哌啶)丙胺混合盐酸；N-苯基-N-(4-哌啶基)哌啶酰胺；N-苯基-N-(4-哌啶)丙酰胺；N-苯基-N-(4-哌啶基)哌啶酰胺,98%；N-苯基-N-
• 英文名称: Norfentanyl
• 英文别名: N-phenyl-N-(piperidin-4-yl)propionamide；N-(4-piperidinyl)propionanilide；N-phenyl-N-(4-piperidinyl) propanamide；N-phenyl-N-(4-piperidyl)propanamide；4-(N'-phenyl-N'-propionyl)-amino-piperidine；N-phenyl-N-piperidin-4-ylpropanamide
• CAS: 1609-66-1
• 化学式: C₁₄H₂₀N₂O
• 分子量: 232.326
• InChiKey: PMCBDBWCQQBSRJ-UHFFFAOYSA-N

物化性质

• 稳定性/保质期：
  常温常压下稳定，避免氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

ADMET

代谢

去甲芬太尼是芬太尼的一个已知人体代谢物。

Norfentanyl is a known human metabolite of fentanyl.

来源:NORMAN Suspect List Exchange

反应信息

• 作为反应物：
  描述：

  N-苯基-N-(4-哌啶)丙胺 混合盐酸 在 N-甲基吗啉 、 (benzotriazole-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 1-羟基苯并三唑 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.33h， 生成
  参考文献：
  名称：

  Development of Potent μ and δ Opioid Agonists with High Lipophilicity

  摘要：

  An SAR study on the Dmt-substituted enkephalin-like tetrapeptide with a N-phenyl-N-piperidin-4-ylpropionamide moiety at the C-terminal was performed and has resulted in highly potent ligands at mu and delta opioid receptors In general, ligands with the substitution of D-Nle(2) and halogenation of the aromatic ring of Phe(4) showed highly increased opioid activities Ligand 6 with good biological activities in vitro demonstrated potent in vivo antihyperalgesic and antiallodynic effects in the tail-flick assay

  DOI：

  10.1021/jm100982d
• 作为产物：
  描述：

  N-(1-Benzyl-4-piperidyl)-N-phenylpropanamide Hydrochloride 在 palladium 10% on activated carbon 、 氢气 、 sodium hydroxide 作用下， 以 甲醇 、 水 、 溶剂黄146 为溶剂， 生成 N-苯基-N-(4-哌啶)丙胺 混合盐酸
  参考文献：
  名称：

  N-（1-苯乙基-4-哌啶基）丙酰苯胺（芬太尼）及其1-取代类似物在瑞士白化病小鼠中的合成及比较生物功效

  摘要：

  芬太尼[ N-（1-苯乙基-4-哌啶基）丙酰苯胺]是一种流行的麻醉镇痛剂，在世界范围内都在临床上使用。然而，由于剂量过量和狭窄的治疗指数，芬太尼及其几种类似物已在人类中引起滥用和死亡。本研究报告了芬太尼及其四个类似物，即N-（1-丙基-4-哌啶基）丙酰苯胺（1），N-（1-（2-苯氧基乙基）-4-哌啶基）的合成和比较生物功效。丙酰苯胺（2），N-（1-（3-（苯氧丙基）-4-哌啶基）丙酰苯胺（3）和N-（1-（2-氰基乙基）-4-哌啶基）丙酰苯胺（4），其中芬太尼的苯乙基链被不同的官能团取代，即烷基，醚基和腈基。通过三种不同的途径确定化合物的中值致死剂量（LD 50），发现所有类似物比芬太尼更安全。通过对中枢神经系统，周围神经系统和自主神经系统自发活动的观察评估，发现所有类似物均与芬太尼相似。此外，所有类似物的神经毒性作用均被盐酸纳洛酮（阿片类药物拮抗剂）逆转，证实它们的作用是通过阿片样物

  DOI：

  10.1007/s00044-012-0390-6

文献信息

• [EN] COMPOSITIONS, DOSAGE FORMS, AND COADMINISTRATION OF AN OPIOID AGONIST COMPOUND AND AN ANALGESIC COMPOUND<br/>[FR] COMPOSITIONS, FORMES GALÉNIQUES ET COADMINISTRATION D'UN COMPOSÉ AGONISTE OPIOÏDE ET D'UN COMPOSÉ ANALGÉSIQUE
  申请人：NEKTAR THERAPEUTICS

  公开号：WO2013070617A1

  公开（公告）日：2013-05-16

  The present invention relates generally to the co-administration of an opioid agonist compound and an analgesic compound. In addition, the invention relates to, among other things, dosage forms for co-administration of an opioid agonist compound and an analgesic compound, methods for administering an opioid agonist compound and an analgesic compound, compositions comprising an opioid agonist compound and an analgesic compound, dosage forms comprising an opioid agonist compound and an analgesic compound, and so on.

  本发明一般涉及阿片受体激动剂化合物和镇痛化合物的联合给药。此外，该发明涉及阿片受体激动剂化合物和镇痛化合物的联合给药的剂型，给药阿片受体激动剂化合物和镇痛化合物的方法，包含阿片受体激动剂化合物和镇痛化合物的组合物，包含阿片受体激动剂化合物和镇痛化合物的剂型等。
• N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists
  申请人：——

  公开号：US20040002504A1

  公开（公告）日：2004-01-01

  The present invention provides a method of treatment of a subject suffering from a disease, such as schizophrenia, for which the administration of an NK-3 antagonist is indicated which comprises administering to that subject a therapeutically effective amount of a compound of formula I: 1 wherein, generally, Q is 2 R 1 is benzyl, phenyl, thiophene or imidazolyl optionally substituted with C 1-4 alkyl or halogen, such as methyl, fluorine or bromine; R 2 is hydrogen or C 1-4 alkyl such as methyl; R 3 is phenyl; R 4 is hydrogen; R 5 is hydrogen or C 1-6 alkylcarbonyl such as methylcarbonyl; X is —SO 2 — or —C(O)N(R 2 )SO 2 — where R 2 is preferably hydrogen; Y is a bond, CH 2 or Z 1 where Z 1 is —N(R f )— in which R f is C 1-6 alkylcarbonyl such as ethylcarbonyl; and R 6 is phenyl, pyrazolyl, pyridyl, pyrimidinyl or benzimidazolonyl optionally substituted with one or two groups chosen from C 1-6 alkyl and benzyl, such as methyl, ethyl and benzyl; or a pharmaceutically acceptable salt thereof.

  本发明提供了一种治疗患有疾病（如精神分裂症）的受试者的方法，其中该疾病的治疗需要使用NK-3拮抗剂，包括向该受试者施用化合物I的治疗有效量： 1 其中，通常情况下， Q是 2 R 1 是苄基、苯基、噻吩或咪唑基，可选择地用C 1-4 烷基或卤素（如甲基、氟或溴）取代； R 2 是氢或C 1-4 烷基，如甲基； R 3 是苯基； R 4 是氢； R 5 是氢或C 1-6 烷基羰基，如甲基羰基； X是—SO 2 —或—C(O)N(R 2 )SO 2 —，其中R 2 最好是氢； Y是键、CH 2 或Z 1 ，其中Z 1 是—N(R f )—，其中R f 是C 1-6 烷基羰基，如乙基羰基；以及 R 6 是苯基、吡唑基、吡啶基、嘧啶基或苯并咪唑基，可选择地用来自C 1-6 烷基和苄基的一个或两个基团取代，如甲基、乙基和苄基； 或其药学上可接受的盐。
• Borrowing Hydrogen in Water and Ionic Liquids: Iridium-Catalyzed Alkylation of Amines with Alcohols
  作者：Ourida Saidi、A. John Blacker、Gareth W. Lamb、Stephen P. Marsden、James E. Taylor、Jonathan M. J. Williams

  DOI：10.1021/op100024j

  日期：2010.7.16

  The use of [Cp*IrI2]2 as an efficient catalyst for the alkylation of amines by alcohols in either water or ionic liquid is described. Primary amines are converted into secondary amines, and secondary amines into tertiary amines in the absence of base, and the chemistry has been applied to the synthesis of the analgesic fentanyl. The conversion of primary amines into N-heterocycles by the reaction with

  描述了使用[Cp * IrI 2 ] 2作为在水或离子液体中通过醇使胺烷基化的有效催化剂。在不存在碱的情况下，伯胺被转化为仲胺，仲胺被转化为叔胺，并且该化学方法已经应用于止痛药芬太尼的合成。还描述了通过与二醇反应将伯胺转化为N-杂环以及磺酰胺的N-烷基化。
• Rifamycin analogs and uses thereof
  申请人：van Duzer H. John

  公开号：US20050043298A1

  公开（公告）日：2005-02-24

  The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3′-hydroxy analogs, 4′-and/or 6′ halo and/or alkoxy analogs, and various 5′ substituents that incorporate a cyclic amine moiety.

  这项发明涉及利福霉素类似物，可用作治疗或预防各种微生物感染的治疗药物。在一种形式中，这些类似物在25位点上乙酰化，就像利福霉素一样。在另一种形式中，这些类似物在25位点上去乙酰化。在其他形式中，苯并噁唑利福霉素、苯并噻唑利福霉素和苯并二唑利福霉素类似物在苯环的各个位置上进行衍生化，包括3'-羟基类似物、4'-和/或6'卤代和/或烷氧基类似物，以及各种包含环胺基团的5'取代基。
• 1-(1,2-disubstituted pipeidinyl)-4-substituted piperidine derivatives
  申请人：Janssen Pharmaceutica N.V.

  公开号：US06346540B1

  公开（公告）日：2002-02-12

  The present invention concerns compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and stereochemically isomeric forms thereof, wherein n is 0, 1 or 2; m is 1 or 2, provided that if m is 2, then n is 1; p is 0, 1 or 2; ═Q is ═O or ═NR3; X is a covalent bond or a bivalent radical of formula —O—, —S—, —NR3—; R1 is Ar1; Ar1C1-6alkyl or di(Ar1)C1-6alkyl, wherein each C1-6alkyl group is optionally substituted with hydroxy, C1-4alkyloxy, oxo or a ketalized oxo substituent of formula —O—CH2—CH2—O— or —O—CH2—CH2—CH2—O—; R2 is Ar2; Ar2C1-6alkyl; Het or HetC1-6alkyl; R3 is hydrogen or C1-6alkyl; R4 is hydrogen; C1-4alkyl; C1-4alkyloxyC1-4alkyl; hydroxyC1-4alkyl; carboxyl; C1-4alkyloxycarbonyl or Ar3; R5 is hydrogen; hydroxy; Ar3; Ar3C1-6alkyloxy; di(Ar3)C1-6alkyloxy; Ar3C1-6alkylthio; di(Ar3)C1-6alkylthio; Ar3C1-6alkylsulfoxy; di(Ar3)C1-6alkylsulfoxy; Ar3C1-6alkylsulfonyl; di(Ar3)C1-6alkylsulfonyl; —NR7R8; C1-6alkyl substituted with —NR7R8; or a radical of formula (a-1) or (a-2); R4 and R5 may also be taken together; R6 is hydroxy; C1-6alkyloxy; C1-6alkyl or Ar3C1-6alkyl; Ar1, Ar2 and Ar3 are phenyl or substituted phenyl; Ar2 is also naphtalenyl; and Het is an optionally substituted monocyclic or bicyclic heterocycle; as substance P antagonists; their preparation, compositions containing them and their use as a medicine.

  本发明涉及以下式的化合物 其中n为0、1或2；m为1或2，但如果m为2，则n为1；p为0、1或2；═Q为═O或═NR3；X为配位键或式的二价基团—O—、—S—、—NR3—；R1为Ar1；Ar1C1-6烷基或二(Ar1)C1-6烷基，其中每个C1-6烷基基团可选择地用羟基、C1-4烷氧基、氧代基或式的缩醛基团取代—O—CH2—CH2—O—或—O—CH2—CH2—CH2—O—；R2为Ar2；Ar2C1-6烷基；Het或HetC1-6烷基；R3为氢或C1-6烷基；R4为氢；C1-4烷基；C1-4烷氧基C1-4烷基；羟基C1-4烷基；羧基；C1-4烷氧羰基或Ar3；R5为氢；羟基；Ar3；Ar3C1-6烷氧基；二(Ar3)C1-6烷氧基；Ar3C1-6烷硫基；二(Ar3)C1-6烷硫基；Ar3C1-6烷磺氧基；二(Ar3)C1-6烷磺氧基；Ar3C1-6烷磺基；二(Ar3)C1-6烷磺基；—NR7R8；用—NR7R8取代的C1-6烷基；或式的基团(a-1)或(a-2)；R4和R5也可结合在一起；R6为羟基；C1-6烷氧基；C1-6烷基或Ar3C1-6烷基；Ar1、Ar2和Ar3为苯基或取代苯基；Ar2也为萘基；Het为可选择地取代的单环或双环杂环；作为P物质拮抗剂；它们的制备、含有它们的组合物以及它们作为药物的用途。